This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Greenberg: Wall Street Defends Stericycle

SAN DIEGO (TheStreet) -- No surprise department: In the wake of yesterday's piece here wondering whether the Feds have launched a criminal investigation of Stericycle (SRCL - Get Report), analysts were out in lockstep defending the company.

My story revolved around a belching incinerator in Utah, which handles all medical waste from the West Coast.

Here is a smattering of comments:

Must Read: Greenberg: Have Feds Launched Criminal Probe of Stericycle?

  • CSFB: "Materiality Is Minimal. We estimate that less than 10% of SRCL volumes are incinerated and this is only one out of eight incinerators, so volume is immaterial. We would also note that part of the volumes that go to incinerators do so in order to keep the facility at 100% capacity. SRCL has the option of redirecting some waste to autoclaving and other disposal alternatives if need be. We view movement of the facility as a last resort option."
  • Stifel: "We believe the stock reaction is overblown. We believe Stericycle's main issue is political, not financial, and the financial impact to the company is not likely to be material."
  • William Blair: " also referenced a potential criminal investigation, which we believe may relate to prior comments that internal tests were manipulated (again, as frequently reported in the local press) to improve test results; however, we have not been able to confirm if this is indeed the case and do not believe any criminal investigation is underway." The analyst added: "From a capacity standpoint, we believe that less than 10% of the company's medical waste is currently incinerated, and we estimate the Utah plant is less than 20% of the company's U.S. incineration capacity. Thus, even if the plant is closed, we believe it would only affect overall treatment capacity by 1% to 2%, and we believe this waste could easily be sent to other facilities."

Reality Check: An avalanche of analyst defense is to be expected. It's unclear if they were regurgitating what Stericycle told them. What I do know: Stericycle didn't return my calls pre-publication and didn't contact me, post-publication, to suggest that the impact would be minimal. Further, the Blair analyst makes it seem like it would be a no-brainer for the company to transport the waste to another facility further East. In his report, he says Stericycle could "likely just increase pricing to offset the higher fuel costs; it has the right to do so in most contracts." Maybe so, but price increases at Stericycle are a touchy subject these days after it settled a whistleblower lawsuit in New York on allegations that it overcharged state and local facilities. This, in my opinion, remains one to watch.

-- Written by Herb Greenberg 

Herb Greenberg, editor of Herb Greenberg's Reality Check, is a contributor to CNBC. He does not own shares, short or trade shares in an individual corporate security.


Chart of I:DJI
DOW 17,711.66 -119.10 -0.67%
S&P 500 2,070.15 -5.66 -0.27%
NASDAQ 4,794.9830 -10.3080 -0.21%

Herb's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs